ALMS
Alumis Inc. Common Stock
$22.02
-0.15
(-0.68%)
Mkt Cap
2.72B
Volume
502,299
52W Range
2.76-30.6
Sector
Healthcare
Beta
-0.29
EPS (TTM)
-1.91
P/E Ratio
-34.11
Revenue (TTM)
8.40M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 24.05M | 0 | 0 | 0 |
| Net Income | (243.32M) | (294.23M) | (154.99M) | (111.93M) |
| EPS | -2.86 | -10.38 | -2.99 | -14.93 |
| Free Cash Flow | (370.18M) | (256.81M) | (134.47M) | (110.13M) |
| FCF / Share | -0.44 | -9.06 | -2.59 | -14.69 |
| Operating CF | (369.52M) | (255.08M) | (129.97M) | (107.72M) |
| Total Assets | 411.94M | 340.99M | 89.61M | 108.17M |
| Total Debt | 36.91M | 30.72M | 32.58M | 1.78M |
| Cash & Equiv | 89.67M | 169.53M | 46.00M | 25.61M |
| Book Value | 301.30M | 260.10M | (339.26M) | (195.24M) |
| Return on Equity | -0.81 | -1.13 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.74M | 1.93M | 2.07M | 2.67M | 17.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.05M) | (92.93M) | (110.75M) | 59.32M | (98.96M) | (94.76M) | (93.12M) | (56.51M) | (49.85M) | (39.30M) | (43.38M) | (36.29M) |
| EPS | -0.74 | -0.89 | -1.06 | 0.78 | -1.82 | -1.74 | -1.73 | -1.04 | -0.96 | -0.76 | -1.13 | -0.70 |
| Free Cash Flow | (87.25M) | (71.91M) | (110.91M) | (106.97M) | (80.39M) | (75.13M) | (84.55M) | (52.72M) | (44.42M) | (34.94M) | (35.41M) | (29.16M) |
| FCF / Share | -0.70 | -0.69 | -1.07 | -1.40 | -1.48 | -1.40 | -1.57 | -0.97 | -0.86 | -0.67 | -0.92 | -0.56 |
| Operating CF | (87.08M) | (71.91M) | (110.91M) | (106.35M) | (80.36M) | (74.76M) | (83.77M) | (52.29M) | (44.26M) | (33.73M) | (33.25M) | (28.33M) |
| Total Assets | 671.59M | 411.94M | 488.01M | 610.92M | 261.30M | 340.99M | 412.56M | 265.18M | 177.38M | 89.61M | N/A | N/A |
| Total Debt | 35.66M | 36.91M | 37.80M | 38.78M | 31.88M | 30.72M | 31.10M | 31.57M | 32.08M | 32.58M | N/A | N/A |
| Cash & Equiv | 63.88M | 89.67M | 65.26M | 151.75M | 128.54M | 169.53M | 213.42M | 155.11M | 112.07M | 46.00M | N/A | N/A |
| Book Value | 567.02M | 301.30M | 384.77M | 485.33M | 168.31M | 260.10M | 348.39M | (438.75M) | (385.93M) | (339.26M) | N/A | N/A |
| Return on Equity | -0.16 | -0.31 | -0.29 | 0.12 | -0.59 | -0.36 | -0.27 | N/A | N/A | N/A | N/A | N/A |
ALMS News
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Alumis to Present at the Leerink Partners Global Healthcare Conference
AXQ Capital LP Invests $78,000 in Alumis Inc. $ALMS